[{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BioLexis Pte. Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BioLexis Pte. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Announces Publication Assessing the Role of Emixustat Hydrochloride in Retinal Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 INVIGORATE Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Partner Updates on Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Receives Formulation Patent Extending NCX 470 U.S","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announce current Status of BLA Review of FYB201","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences to Present KSI-301 Phase 1b Clinical Study Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Safety, Efficacy and Durability Data","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acucela Provides Update on Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Sustained-Release Implant","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Kala Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kala Pharma Announces Significant Results in STRIDE 3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kala Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Kala Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Kala Pharm.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"National Securities Corporation","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Private Placement","leadProduct":"Pilocarpine Hydrochloride","moa":"Muscarinic M3 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eyenovia \/ National Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Mimetogen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mimetogen Pharmaceuticals Completes Enrollment of MIM-728 Phase 3 Trial for Tavilermide for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Tavilermide","moa":"TrkA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mimetogen Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mimetogen Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mimetogen .."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Publication Describes Mechanism of Action for T?4 in Corneal Wound Healing and Regeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Cloudbreak Therapeutics","sponsor":"V-Capital","pharmaFlowCategory":"D","amount":"$25.4 million","upfrontCash":"Undisclosed","newsHeadline":"V-Capital Leads $25M New Round In Ocular Drug Developer Cloudbreak Therapeutics","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Series B Financing","leadProduct":"CBT-001","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Cloudbreak Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Cloudbreak Therapeutics \/ V-Capital","highestDevelopmentStatusID":"10","companyTruncated":"Cloudbreak.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xbrane Biopharma Plans to Continue Phase III Trial of its Xlucane\u00ae (Ranibizumab) Biosimilar Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGF A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Xbrane Biopharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Xbrane Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Xbrane Bio.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 Announces Results of Phase 3 Clinical Trial of DEXTENZA\u00ae for the Treatment of Ocular Itching in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kubota Vision Completes Enrollment in the Emixustat Phase 3 Clinical Trial in Patients with Stargardt Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Emixustat Hydrochloride","moa":"RPE65","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kubota Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pha.."},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bausch + Lomb Licenses Exclusive Rights from STADA and Xbrane to a Biosimilar Candidate for Lucentis in the United States and Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzn.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocular Therapeutix\u2122 To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocular Therapeutix","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0,"dosageForm":"Intracanalicular Insert","sponsorNew":"Ocular Therapeutix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocular The.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ReGenTree Announces Efficacy Results of the Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Formycon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Formycon Announces Update On Biosimilar Programs","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Formycon","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Formycon \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Formycon \/.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Phase 3 Trial of Ranibizumab Biosimilar Candidate, SB11 to Treat Namd Meets Primary Endpoints","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures LLC","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 \/ LYTENAVA\u2122 (bevacizumab-vikg)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures LLC","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Th.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"U.S FDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aldeyra Therapeutics Reaches Agreement with the US FDA for the Use of RASP as an Objective Sign for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ U.S FDA","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Methotrexate","moa":"DHFR","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis' Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"NTC","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"NTC \/ Taro Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"NTC \/ Taro.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Rexahn Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"$21.1 million","upfrontCash":"Undisclosed","newsHeadline":"Rexahn and Ocuphire Enter into Definitive Merger Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Merger","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Rexahn","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Begins Phase 3 Trial for Aflibercept Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"PL9643","moa":"Melanocortin 1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Palatin Technologies","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Palatin Te.."},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"7-day Levofloxacin\/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Levofloxacin","moa":"DNA gyrase","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Antibiotic","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pha.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Abicipar Pegol","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Allergan Aesthetics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Allergan Aesthetics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Allergan A.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"GHO Capital","pharmaFlowCategory":"D","amount":"$5.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"NCX 470","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ GHO Capital","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GenSight Reports Final REALITY Natural History Study Results Confirming Poor Spontaneous Recovery for LHON Patients With ND4 Mutation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenadogene nolparvovec","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GenSight Biologics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GenSight B.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Arctic Vision","pharmaFlowCategory":"D","amount":"$46.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eyenovia and Arctic Vision Ink License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Arctic Vision","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Mitotech","sponsor":"Essex Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 \u2013 a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Visomitin","moa":"Cardiolipin peroxidation","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Mitotech","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Mitotech \/ Essex Bio","highestDevelopmentStatusID":"10","companyTruncated":"Mitotech \/.."},{"orgOrder":0,"company":"GtreeBNT","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture GtreeBNT Expects to Complete Phase 3 Dry Eye Trial in November 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"GtreeBNT","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"GtreeBNT \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GtreeBNT \/.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Orasis Pharmaceuticals","sponsor":"Bluestem Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orasis Raises $30 Million to Advance the Clinical Development of Novel Treatment for Presbyopia","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Series C Financing","leadProduct":"CSF-1","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Orasis Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Eye Drop","sponsorNew":"Orasis Pharmaceuticals \/ Bluestem Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orasis Pha.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Provides Update on the FDA Review of EM-100","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ketotifen Fumarate","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Opthea","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opthea Files for a $150 Million US IPO","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0.14999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ U.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Eyenovia","sponsor":"Bausch Health","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"$10.0 million","newsHeadline":"Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Eyenovia","amount2":0.050000000000000003,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Eye Drop","sponsorNew":"Eyenovia \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Eyenovia \/.."},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparc Reports Positive Top-Line Results of Phase 3 Clinical Trial of SDN-037","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"SDN-037","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sun Pharma.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ARISE-3 Phase 3 Trial Completion Expected by End of 2020","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Essex Biotechnology","sponsor":"Henlius","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"$10.0 million","newsHeadline":"Essex and Henlius Ink Global Co-Development and License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Essex Biotechnology","amount2":0.029999999999999999,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Essex Biotechnology \/ Henlius","highestDevelopmentStatusID":"10","companyTruncated":"Essex Biot.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"ReGenTree","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RegeneRx Expects to Complete Short-Term Financing While Awaiting Completion of Phase 3 Clinical Trial for Dry Eye Syndrome","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Financing","leadProduct":"RGN-259","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ ReGenTree","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Zhaoke Ophthalmology","sponsor":"Nevakar","pharmaFlowCategory":"D","amount":"$102.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nevakar and Zhaoke Ophthalmology Enter into Licensing Agreement for NVK-002 (Atropine to Treat Progression of Myopia in Children)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke Ophthalmology","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Zhaoke Ophthalmology \/ Nevakar","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke Oph.."},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aldeyra Th.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"OcuMension Therapeutics \/ Nicox SA","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Apellis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$1,245.0 million","upfrontCash":"$250.0 million","newsHeadline":"Sobi and Apellis Enter Collaboration for Global Co-Development and Ex-Us Commercialisation of Systemic Pegcetacoplan in Rare Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Pegcetacoplan","moa":"Complement C3","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Apellis Pharmaceuticals","amount2":1.25,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Apellis Pharmaceuticals \/ Sobi","highestDevelopmentStatusID":"10","companyTruncated":"Apellis Ph.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Tetraphase Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Reproxalap","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tetraphase Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Tetraphase Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetraphase.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Shandong Boan Biological Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OcuMension Therapeutics \/ Shandong Boan Biological Technology","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"ReGenTree","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"ReGenTree","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"ReGenTree \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"ReGenTree .."},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ Ocumension Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at AAO 2020 Virtual Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Zhaoke","sponsor":"Nevakar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"HONG KONG","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Zhaoke","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Zhaoke \/ Nevakar Inc","highestDevelopmentStatusID":"10","companyTruncated":"Zhaoke \/ N.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Ocuphire Pharma Announces Expansion of Global Patents for Nyxol\u00ae and $1.7 Million NIH Grants for APX3330 Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Funding","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Unveils Final Results of Phase 3 Clinical Trial for SB11","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Presents Data on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Meeting","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"Kodiak Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b\/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"KSI-301","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kodiak Sciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kodiak Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kodiak Sci.."},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept in Patients with Moderate-to-Severe Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"TNF alpha","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nona Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nona Biosciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nona Biosc.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Oculos Development Services","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol\u00ae for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Oculos Development Services","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Biogen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Accepts for Review Samsung Bioepis & Biogen\u2019s BLA for SB1, a Proposed Biosimilar Referencing Lucentis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Samsung Bioepis \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bi.."},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch Health Starts Second Phase 3 Study For NOV03 For Dry Eye Disease Associated With Meibomian Gland Dysfunction","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch Health","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bausch Hea.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"HBM Healthcare Investments","pharmaFlowCategory":"D","amount":"$18.1 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox Raises \u20ac15 million in Private Placement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Private Placement","leadProduct":"NCX 470","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0.02,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.02,"dosageForm":"Ophthalmic Solution","sponsorNew":"Nicox SA \/ HBM Healthcare Investments","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"Oyster Point Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oyster Point Pharma Submits New Drug Application to U.S FDA for OC-01 Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Oyster Point Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Oyster Point Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Oyster Poi.."},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche\u2019s Faricimab Meets Primary Endpoint in Two Global Phase III Studies for Diabetic Macular Edema","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Faricimab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffman.."},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Conbercept: New Generation of Product for Treatment of nAMD Completes 36-week Primary Endpoint Visits of Phase III Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Conbercept","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Ka.."},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Cetirizine","moa":"H1 receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"OcuMension Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"ophthalmic solution","sponsorNew":"OcuMension Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"OcuMension.."},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Adapalene","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Ph.."},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol\u00ae for Reversal of Mydriasis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Phentolamine Mesylate","moa":"Adrenergic receptor alpha-1\/alpha-2","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Ocuphire Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Ocuphire Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocuphire P.."},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glaukos\u2019 iDose\u00ae TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Intraocular implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ .."},{"orgOrder":0,"company":"Nevakar","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Nevakar and Th\u00e9a Enter into Licensing Agreement for the Commercialization of NVK-002 in Europe","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nevakar","amount2":0.14000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Nevakar \/ Laboratoires Th\u00e9a","highestDevelopmentStatusID":"10","companyTruncated":"Nevakar \/ .."},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Novaliq","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bausch + Lomb Completes Enrollment of First Phase 3 Study for NOV03 (Perfluorohexyloctane)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Perfluorohexyloctane","moa":"Lipid layer","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Bausch & Lomb Incorporated","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Bausch & Lomb Incorporated \/ Novaliq","highestDevelopmentStatusID":"10","companyTruncated":"Bausch & L.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Comments on ARISE-3 Clinical Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"Opthea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Opthea Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"OPT-302","moa":"VEGF C\/D","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Opthea","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Opthea \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Opthea \/ N.."},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boan Biotech Completes First Patient Dosing in Phase \u2162 Clinical Trial for LY09004, Multiple R&D Projects Under Intensive Development","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Aflibercept","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Luye Pharma","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Luye Pharm.."},{"orgOrder":0,"company":"Arctic Vision","sponsor":"Loyal Valley Capital","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Triamcinolone Acetonide","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Arctic Vision","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"Steroid","amount2New":0.10000000000000001,"dosageForm":"Suprachoroidal Injection","sponsorNew":"Arctic Vision \/ Loyal Valley Capital","highestDevelopmentStatusID":"10","companyTruncated":"Arctic Vis.."},{"orgOrder":0,"company":"Nicox SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"NCX 470","moa":"sGC","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Nicox SA","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Ophthalmic solution","sponsorNew":"Nicox SA \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Nicox SA \/.."},{"orgOrder":0,"company":"AffaMed Therapeutics","sponsor":"Lake Bleu Capital","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"Undisclosed","newsHeadline":"AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2021","year":"2021","type":"Series B Financing","leadProduct":"Ranibizumab","moa":"VEGFA","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"AffaMed Therapeutics","amount2":0.17000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.17000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"AffaMed Therapeutics \/ Lake Bleu Capital","highestDevelopmentStatusID":"10","companyTruncated":"AffaMed Th.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"RegeneRx Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RegeneRx B.."},{"orgOrder":0,"company":"RegeneRx Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RegeneRx Issues Update on ARISE-3 Trial","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Thymosin Beta-4","moa":"Laminin-5 synthesis","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"RegeneRx Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III
Market Place